Pfizer settled a nearly 10-year battle Wednesday, announcing a $2.15 billion settlement with Teva Pharmaceuticals Industries and Sun Pharmaceutical Industries for patent infringement on its acid-reflux drug Protonix.
Japan's Takeda Pharmaceutical Co Ltd, Pfizer's partner on the drug, will receive 36 percent or about $774 million from the settlement.
Pfizer won a protracted 10-year legal battle in April 2010 when a New Jersey jury ruled that Teva had infringed the Protonix patent. Teva started selling a generic version of the drug in 2007.
A trial to determine damages began on Monday.
(Read More: Options Action: A Bullish Bet on Pfizer)